Impact Factor 2020: 1.226 (@Clarivate Analytics)
5-Year Impact Factor: 2.285 (@Clarivate Analytics)
Immediacy Index: 2.645
  • Users Online: 2247
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2021  |  Volume : 14  |  Issue : 9  |  Page : 401-409

COVID-19-associated mucormycosis and treatments


1 Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jalan SP 2, Bandar Saujana Putra, 42610 Jenjarom Selangor, Malaysia
2 Faculty of Pharmacy & Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong 08100, Kedah, Malaysia
3 Jeffrey Cheah School of Medicine & Health Sciences, Monash University, Selangor 47500, Malaysia
4 College of Pharmacy, National University of Science and Technology, 130 Muscat, Sultanate of Oman
5 Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh 30450, Malaysia
6 Faculty of Applied Science & Centre of Excellence for Biomaterials Engineering, AIMST University, Kedah, Bedong 08100, Malaysia
7 Centre for Virus and Vaccine Research & Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Selangor 47500, Malaysia
8 Faculty of Medicine, AIMST University, Kedah 08100, Malaysia
9 School of Pharmaceutical Sciences (LIT-Pharmacy), Lovely Professional University, Jalandhar 144411, India
10 Department of Pharmacy, SMAS, Galgotias University, Greater Noida 203201, India
11 Department of Pharmaceutical Sciences, Gurukul Kangri, Haridwar, Uttarakhand 249404, India

Correspondence Address:
Neeraj Kumar Fuloria
Faculty of Pharmacy & Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong 08100, Kedah
Malaysia
Shivkanya Fuloria
Faculty of Pharmacy & Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong 08100, Kedah
Malaysia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.326253

Get Permissions

In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed738    
    Printed8    
    Emailed0    
    PDF Downloaded118    
    Comments [Add]    

Recommend this journal